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Cationic drug transportersOrganic cation transporters (OCT1–3)mediate the transport of organic cations including inhaled drugs across the
cell membrane, although their role in lung epithelium hasn't been well understood yet. We address here the ex-
pression and functional activity of OCT1–3 in human airway epithelial cells A549, Calu-3 and NCl-H441. Kinetic
and inhibition analyses, employing [3H]1-methyl-4-phenylpyridinium (MPP+) as substrate, and the compounds
quinidine, prostaglandine E2 (PGE2) and corticosterone as preferential inhibitors of OCT1, OCT2, and OCT3, re-
spectively, have been performed. A549 cells present a robust MPP+ uptake mediated by one high-afﬁnity com-
ponent (Km ~ 50 μM) which is identiﬁable with OCT3. Corticosterone, indeed, completely inhibits MPP+
transport, while quinidine and PGE2 are inactive and SLC22A3/OCT3 silencing with siRNA markedly lowers
MPP+ uptake. Conversely, Calu-3 exhibits both a high (Km b 20 μM) and a low afﬁnity (Km N 0.6 mM) transport
components, referable to OCT3 and OCT1, respectively, as demonstrated by the inhibition analysis performed at
proper substrate concentrations and conﬁrmed by the use of speciﬁc siRNA. These transporters are active also
when cells are grown under air–liquid interface (ALI) conditions. Only a very modest saturable MPP+ uptake
is measurable in NCl-H441 cells and the inhibitory effect of quinidine points to OCT1 as the subtype functionally
involved in this model. Finally, the characterization of MPP+ transport in human bronchial BEAS-2B cells sug-
gests that OCT1 and OCT3 are operative. These ﬁndings could help to identify in vitro models to be employed
for studies concerning the speciﬁc involvement of each transporter in drug transportation.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Membrane transporters are known to have a signiﬁcant impact on
the absorption and elimination of a large number of drugs, determining
their pharmacokinetic proﬁles, safety and efﬁcacy [1]. A large family of
transporters are the Solute Link Carrier, SLC22A, which are often
found in epithelial membranes where they mediate uptake and secre-
tion of organic cations [2]. SLC22A gene family includes electrogenic
transporters (i.e. OCT1/SLC22A1, OCT2/SLC22A2, and OCT3/SLC22A3)
and pH-dependent novel transporters, namely OCTN1/SLC22A4 and
OCTN2/SLC22A5 [3]. Although OCTNs may mediate the transport of
cationic chemicals, they are most notably known for their ability to
mediate the inﬂux of carnitine, and several mutations in the SLC22A5, Earle's Balanced Salt Solution;
n transporter; PBS, phosphate-
nsepithelial electrical resistance
rale, Dipartimento di Scienze
versità degli Studi di Parma, Via
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.gene have been identiﬁed in patients with primary carnitine deﬁciency
[4]. OCTs are involved in the bidirectional translocation of small
(b500 Da) organic cations across the cell membrane. They are endowed
with broad, overlapping afﬁnities for a wide range of substrates, includ-
ing endogenous molecules, such as choline, creatinine and neurotrans-
mitters [5], as well as a variety of xenobiotics [6]. The model
substrates for the functional study of OCTs are tetraethylammonium
(TEA) and the most speciﬁc neurotoxin methyl 4-phenylpiridinium
(MPP+) [5,7]. None of the substrates thus far employed interacts only
with a single OCT transporter, as demonstrated employing transfected
cell models, such as CHO [8], HEK293 [9,10] or xenopus oocytes
[11–13]. In non transfected cell models the characterization of OCT
transport activity appears further complicated by the lack of speciﬁc in-
hibitors too [5]. The study of OCT transporters has been mainly focused
on liver, kidneys, intestine and blood–brain barrier, with the lung
remaining largely unchartered terrain, despite its pharmacological rele-
vance [14,15]. Actually, the lung offers a great potential as a portal into
the systemic circulation for drugs endowed with difﬁcult oral pharma-
cokinetics or stability issue. Moreover, since several common inhaled
drugs, positively charged at physiological pH, have been reported to in-
teract with OCT [16], the role of these transporters in lung epithelium
Fig. 1. Time-dependent accumulation ofMPP+ inA549, Calu-3 andNCl-H441 cells. Cells were incubated for the indicated times in the transport buffer (see sectionMaterial andmethods)
containing [3H]MPP+ (10 μM; 2 μCi/ml) (open symbols). Non-speciﬁc binding of the substrate was estimated by measuring [3H]MPP+ uptake in the presence of an excess of unlabelled
substrate (2mM) (ﬁlled symbols). Each point represents themean± S.D. of four independent determinations. The experiments have been repeated three timeswith comparable results.
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tion. Evidence is now emerging that OCTs are involved in transport
processes in various cell types of the lung [17,18], and differential ex-
pression of the transporters has been highlighted in cell models from
different regions [19]. The aim of our study is to identify optimal cell
models for studies concerning cationic drug absorption through OCTs
in the airways. Thus far, the characterization of OCT-mediated transport
in respiratory cell models has been performed employing the ﬂuores-
cent cation Asp+ as substrate [16,20]. However, since also the choice
of the substrate is known to inﬂuence the proﬁle of inhibition of OCT-
mediated uptake both quantitatively and qualitatively [21], it is conceiv-
able that the use of substrates other than Asp+ may broaden the
knowledge about OCT function. In this study we thoroughly character-
ize OCT transport activity in in vitro models of respiratory epithelium
(alveolar A549, bronchial Calu-3, and distal lung NCl-H441 carcinoma
cells, as well as in bronchial BEAS-2B cells) by means of an integrated
approach combining data of mRNA expression with the kinetic and in-
hibition analyses of MPP+ transport.
2. Material and methods
2.1. Cell cultures
Calu-3, A549, NCl-H441 and BEAS-2B cell lines were obtained from
American Type Culture Collection (ATCC, Rockville, MD, USA). Alveolar
carcinoma A549 and immortalized BEAS-2B bronchial epithelial cells
were cultured in Dulbecco's Modiﬁed Eagle Medium (DMEM, high
glucose) supplemented with sodium pyruvate (1mM). NCl-H441, orig-
inally derived from lung papillary adenocarcinoma, were cultured in
RPMI-1640 (ATCC) and used at passages 36–41. Calu-3 cells, deriving
from a human lung adenocarcinoma, were cultured in Eagle'sMinimumFig. 2.MPP+ ﬂuxes in Calu-3 ALI. Monolayers of polarized Calu-3 cells grown in air–liquid inter
ing [3H]MPP+ (10 μM; 2 μCi/ml), either added at the apical or at the basolateral side, as indica
(panel B) were determined as described in the section Material and methods. Each point repre
repeated twice with comparable results.Essential Medium (EMEM) supplemented with sodium pyruvate
(1mM)and used at passages 45–53. For all cellmodels, growthmedium
was supplementedwith 10% fetal bovine serum (FBS) and 1% Penicillin/
Streptomycin. Cell cultures were routinely cultured under physiological
conditions (37.5 °C, 5% CO2, 95% humidity) in 10-cm diameter dishes.
For growth under air–liquid interfaced culture (ALI) conditions,
Calu-3 cells were initially seeded on Cell Culture Inserts (12 mm in di-
ameter, pore size 0.4 μm; Falcon) at the density of 75 × 103 cells/well,
with apical and basolateral ﬂuid volumes corresponding to 250 and
700 μl, respectively. After 24 h, the apical ﬂuidwas completely removed,
and the medium in the basolateral compartment was renewed every
other day. Cell cultures were employed after 21 days, when the cell
monolayers exhibited “tight” barrier properties, as represented by
high transepithelial electrical resistance (TEER N 500 Ohm/cm2,
measured with an epithelial voltmeter (EVOM, World Precision Instru-
ments, FL, USA)). The integrity of cell monolayers was preserved after
the experiments.
2.2. qRT-polymerase chain reaction
For the analysis of mRNA expression 1 μg of total RNA, extracted
with GenElute Mammalian Total RNA Miniprep Kit (Sigma Aldrich),
was reverse-transcribed, and 40 ng of cDNAwas ampliﬁed as described
previously [22]. The following forward and reverse primers were
employed: 5′ TGT CAC CGA AAA GCT GAG CC 3′ and 5′ TCC GTG AAC
CAC AGG TAC ATC 3′ for SLC22A1/OCT1; 5′ CAT CGT CAC CGC GTT
TAA CCT G 3′ and 5′ AGC CGA TAC TCA TAG AGC CAA T 3′ for
SLC22A2/OCT2; 5′ AGG TAT GGC AGG ATC GTC ATT 3′ and 5′ GCA
GGA AGC GGA AGA TCA CA 3′ for SLC22A3/OCT3; 5′ GCA GCC ATC
AGG TAA GCC AAG 3′ and 5′ AGC GGA CCC TCA GAA GAA AGC 3′ for
the housekeeping RPL15 (Ribosomal Protein Like 15). The expressionface conditions (ALI)were incubated for the indicated time in the transport buffer contain-
ted. The intracellular MPP+ accumulation (panel A) and the transcellular ﬂuxes of MPP+
sents the mean ± S.D. of three independent determinations. The experiments have been
Fig. 3. Kinetic analysis of MPP+ uptake. A549, NCl-H441 and Calu-3 cells were incubated
in the presence of the indicated concentrations (from0.8 to 1850 μM)of [3H]MPP+(2 μCi/
ml) for 5 min (A549), 10 min (Calu-3) or 15 min (NCl-H441), in the absence (open sym-
bols) or in the presence (ﬁlled symbols) of Na+. Nonlinear ﬁtting of the data was per-
formed employing Eq. (1) (A549 and NCl-H441 cells) or Eq. (2) (Calu-3 cells) (see
sectionMaterial andmethods). The resulting kinetic constants are given in Table 1. Inserts
in each graph show the Eadie–Hofstee transformations of the saturable uptake (obtained
after subtraction of the diffusive component estimated by the nonlinear ﬁtting). Straight
lines are drawn employing the values of the kinetic parameters given by nonlinear regres-
sion (see Table 1). Curves for Calu-3 represent the nonlinear ﬁtting of the data. Points are
mean ± S.D. of three independent determinations. The experiment has been repeated
twice with comparable results.
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ized to that of the housekeeping gene and shown relatively to its
expression level in a reference sample (=1), as indicated.
2.3. siRNA transfection
Short interfering RNA (siRNA) analysis of SLC22A1/OCT1 and
SLC22A3/OCT3 was performed employing speciﬁc FlexiTube siRNA
(Cat.# 1027416) by Qiagen® (Milano, Italy), according to Fast-Forward
Transfection protocol provided by the manufacturer. Brieﬂy, cells
(1 × 105/ml) were transfected by adding to 1 ml of cell suspension
200 μl of serum free RPMI containing HiPerFect Transfection Reagent
(9 μl) and 100 nM AllStar Negative Control siRNA (Cat.# SI03650318;
scrambled) or 25 nM each of 4 different OCT1 (Cat. # SI04193539,
SI04205390, SI4270483, SI04318811) or OCT3 siRNA (Cat. #
SI00721357, SI04140598, SI04159848, SI04218935). Transfected cells
were seeded as required by the experimental plan, and maintained
under growing conditions for 96 h. Control, untransfected cells were
also cultured in parallel.
2.4. Uptake studies
For uptake assay, 3 × 104 cells were seeded onto 96-well trays
(Falcon) and uptake was measured when the conﬂuence was reached.
Activity of OCTs was determined by measuring the uptake of the
radiolabeled substrate [3H]1-methyl-4-phenylpyridinium (MPP+).
After two rapidwashes in prewarmed transport buffer (Earle's Balanced
Salt Solution (EBSS) containing (inmM) 117 NaCl, 1.8 CaCl2, 5.3 KCl, 0.9
NaH2PO4, 0.8 MgSO4, 5.5 glucose, 26 TRIS–HCl adjusted to pH 7.4), cells
were incubated in transport buffer containing [3H]MPP+ (2 μCi/ml) for
the times detailed in each experiment (see ﬁgure legends). For the
determination of sodium-independent MPP+ uptake, a modiﬁed EBSS
in which NaCl was replaced with equimolar N-methylglucamine.
When required, the inhibitors (corticosterone, prostaglandine E2 and
quinidine) were in the transport buffer at the indicated concentrations.
At the indicated times, transport buffer containing the radiolabeled sub-
strate was removed, and the experiment was terminated by two rapid
washes (b10 s) in ice-cold 300mMurea. Cell monolayers were extract-
ed in ethanol and the radioactivity in cell extracts was determined with
Wallac Microbeta Trilux2 liquid scintillation spectrometer (Perkin
Elmer, Monza, Italy). Protein content was determined directly in the
well using amodiﬁed Lowry procedure [23]. MPP+uptake is expressed
as nmol/mg of protein. No relevant difference in transport rates was ob-
served among cells at different passage number.
The apparent kinetic parameters Km (Michaelis constant) and Vmax
(maximum transport rate) of MPP+ uptake were calculated by non-
linear regression ﬁtting according to the following Michaelis–Menten
equations:
v ¼ Vmax  S½ 
Km þ S½ 
þ Kd  S½  ð1Þ
for a single saturable component plus diffusion, where v is the initial in-
ﬂux, Vmax is the maximal inﬂux, Km is the Michaelis constant and Kd is
the diffusion constant;
v ¼ V max1  S½ 
Km1 þ S½ 
þ V max2  S½ 
Km2 þ S½ 
þ Kd  S½  ð2Þ
for two saturable transport components plus diffusion,where the indices
1 and 2 indicate the high- and low-afﬁnity components, respectively.
Table 1
Kinetic parameters describing the uptake of MPP+.
Data are estimated from nonlinear regression analysis shown in Fig. 3.
High afﬁnity Low afﬁnity
Km1
mM
Vmax1
nmol/mg of protein/min
Km2
mM
Vmax2
nmol/mg of protein/min
A549 Na+-present 0.050 ± 0.0015 1.433 ± 0.016
Na+-absent 0.043 ± 0.0019 1.471 ± 0.022
NCl-H441 Na+-present 0.184 ± 0.018 0.178 ± 0.009
Na+-absent 0.176 ± 0.0138 0.172 ± 0.007
Calu-3 Na+-present 0.014 ± 0.005 0.025 ± 0.005 0.78 ± 0.08 0.269 ± 0.017
Na+-absent 0.020 ± 0.004 0.038 ± 0.004 0.60 ± 0.04 0.240 ± 0.023
Fig. 4. Inhibition of MPP+ uptake in A549 cells. A549 cells were incubated for 5 min in the transport buffer containing [3H]MPP+ (5 μM; 2 μCi/ml) with the indicated concentrations of
inhibitors. Each point represents themean± S.D. of four independent determinations. For corticosterone, data were ﬁtted by Eq. (3) (see sectionMaterial andmethods). The experiment
has been repeated three times with comparable results.
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inhibitors on MPP+ uptake:
v ¼ V0− Imax  I½ 
I½ 0:5 þ I½ 
ð3Þ
where v is the initial inﬂux, v0 is the uptake in the absence of the inhib-
itor, Imax is the maximal inhibition, and [I]0.5 is the inhibitor concentra-
tion required for half-maximal inhibition. The Ki value was calculated
from [I]0.5 employing the following equation:
I½ 0:5 ¼ 1þ
S½ 
Km
 
 Ki ð4ÞFig. 5. Inhibition of MPP+ uptake in NCl-H441 cells. NCl-H441 cells were incubated for
15 min in the transport buffer containing [3H]MPP+ (50 μM; 2 μCi/ml) in the absence
(control) and in the presence of the indicated inhibitors (250 μM). Bars represent the
mean ± S.D. of four independent determinations. The experiments have been repeated
three times with comparable results. *p b 0.05 vs control.2.5. Determination of MPP+ ﬂuxes in polarized Calu-3
Cell monolayers, cultured on permeable supports (Cell Culture
Insert, Falcon), were washed once with EBSS. For the determination of
apical and basolateral uptake, 50 or 600 μl of EBSS containing
[3H]MPP+ (10 μM, 2 μCi) was added to the apical or basolateral
compartment, respectively, while the opposite compartment was incu-
bated in EBSS. For the determination of transcellular ﬂuxes, aliquots of
the solution in the opposite compartmentwere collected and the radio-
activity was measured with a Wallac Microbeta Trilux2 liquid scintilla-
tion spectrometer. To determine the intracellular accumulation of the
substrate, the porous membranes were rapidly washed in 300 mM
ice-cold urea, then detached from the culture inserts. Cell monolayers
were extracted in 0.2 ml ethanol and the radioactivity of cell extracts
was measured with Wallac Microbeta Trilux2 liquid scintillation spec-
trometer. Cell monolayers were then dissolved with 0.5% sodium
deoxycholate in 1 M NaOH, and protein content was determined using
a modiﬁed Lowry procedure, as described previously [23].Fig. 6. Estimated relative contribution of low and high afﬁnity components to MPP+
transport in Calu-3 cells. The curves have been calculated on the basis of the kinetic pa-
rameters presented in Table 1.
Fig. 7. Inhibition of MPP+ uptake in Calu-3 cells. Cells were incubated for 10 min in the
transport buffer containing 5 μM (panel A) or 100 μM (panel B) [3H]MPP+ (2 μCi/ml) in
thepresence of the indicated concentrations of the inhibitors. Data are expressed as percent
of control (absence of inhibitor). Data were ﬁtted by Eq. (3) (see section Material and
methods). Each point represents the mean ± S.D. of four independent determinations.
The experiment has been repeated three times with comparable results.
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Curve ﬁttings were obtained employing Prism® 5.0 software
(GraphPad, San Diego, CA). Unless otherwise stated, all experiments
were performed in quadruplicate and data presented as mean ± SD.
Statistical analysis was done with Prism® 5.0 software, using one-way
ANOVA followed by Bonferroni post-hoc test.2.7. Materials
Fetal bovine serum was purchased from EuroClone (Milano,
Italy). Culture media for NCl-H441 were purchased from (ATCC,
Rockville, MD, USA). Methyl-4-phenylpyridinium iodide, 1-
[methyl-3H], 85 Ci/mmol, was from ARC (American Radiolabeled
Chemicals, St. Luis, MO, USA) and was obtained from Bcs BiotechFig. 8. Effect of pHonMPP+uptake in Calu-3 cells. Cellswere incubated for 10min in the transpo
in thepresence or in the absence of sodium (panels A and C) or in thepresence of sodium(panels
indicated (panels B and D). Each point represents the mean ± S.D. of four independent determi(Cagliari, Italy). Sigma-Aldrich was the source of the inhibitors,
and, unless otherwise speciﬁed, of all other chemicals.
3. Results
3.1. Time-dependent accumulation of MPP+ in A549, Calu-3 and
NCl-H441 cells
The uptake of 1-methyl-4-phenylpyridinium (MPP+) by the three
cell lines has been preliminary measured at different times, up to
60 min (Fig. 1). In A549 MPP+ uptake was linear up to 5 min incuba-
tion, while in Calu-3 cells linearity was maintained up to 15 min.
MPP+ uptake was completely abolished by an excess of unlabelled
substrate, employed to estimate the non-speciﬁc binding. This result
suggests that, at the concentration of the substrate employed, non-
saturable uptake in these cellswas negligible. Conversely,MPP+uptake
in NCl-H441 cells was very low, although slightly increasing up to
30 min, and hardly inhibited by an excess of the substrate. In light of
these results, we can conclude that A549 cells display the highest satu-
rable uptake of MPP+, with Calu-3 following and NCl-H441 endowed
with an only modest saturable uptake.
In addition, time-course of MPP+ uptake performed in polarized
Calu-3 cells grown under air–liquid interface conditions (Calu-3 ALI),
indicated that the accumulation of the substrate was linear up to
30 min and comparable when measured at the apical and basolateral
side of the layers (Fig. 2, panel A). Under these conditions, the trans-
cellular ﬂuxes of MPP+ were detectable in both directions and
quantitatively comparable from apical to basolateral side and vice
versa (panel B).
3.2. Kinetic analysis of MPP+ uptake
Initial rates of transport were determined in the three cell lines over
a wide range of MPP+ concentrations (from 0.8 to 1850 μM), both in
the presence and in the absence of sodium (Fig. 3). Data obtained
under the two experimental conditions were overlapping, thusrt buffer containing 5 μM(panels A andB) or 100 μM(panels C andD) [3H]MPP+(2 μCi/ml)
B andD) at the indicated pH. Carnitineor ergothioneinewas added to the transport buffer as
nations. The experiment has been repeated twice with comparable results.
Fig. 9. Inhibition ofMPP+uptake in Calu-3 ALI. Polarized cells weremaintained under air–liquid interface growth conditions (21 d). Apical and basolateral sidewere incubated for 10min
in the transport buffer containing 5 μM(panels A and B) or 100 μM(panels C andD) [3H]MPP+(2 μCi/ml) in the absence (control) or in the presence of the indicated concentrations of the
inhibitors. Bars represent the mean ± S.D. of three independent determinations. The experiment has been repeated twice with comparable results. *p b 0.05, **p b 0.01 vs control.
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cell models. Transport values in A549 cells were best ﬁtted by Eq. (1)
(see section Material and methods) and the resulting kinetic parame-
ters revealed the presence of a high-afﬁnity transport system plus diffu-
sion (Km about 50 μM with a Vmax of about 1.5 nmol/mg of protein).
Consistently, the Eadie–Hofstee plot of the saturable component (in-
sert) was linear, conﬁrming the operation of a single OCT transporter
in this model. Also in NCl-H441 cells, transport data were best ﬁtted
by Eq. (1) but in this case the Km values were higher (about 180 μM)
and Vmax values about ten times lower than in A549. On the contrary,
in Calu-3 cells, MPP+ transport data were best ﬁtted by Eq. (2), reveal-
ing the presence of at least two saturable transport components, one
displaying a high-afﬁnity for the substrate (Km ≤ 20 μM) and the
other with a low-afﬁnity (Km ≥ 0.6 mM). Accordingly, the regression
analysis of the Eadie–Hofstee plot for the saturable MPP+ uptake in
these cells (insert) appeared nonlinear, conﬁrming the involvement of
at least two different transporters.
A complete description of the apparent kinetic parameters obtained
in the cell models is shown in Table 1.Fig. 10.Expression of OCTmRNA.mRNA levels for OCTswere determined through RT-qPCR anal
the different cell models was expressed relatively to that of A549 (=1). For SLC22A2/OCT2, cD
means ± S.E. of three experiments, each performed in duplicate.3.3. Inhibition analysis of MPP+ uptake
In order to identify the contribution of each OCT to the transport of
MPP+ in the three cell models, the uptake of the substrate was mea-
sured in the presence of increasing concentrations of the inhibitors
quinidine, prostaglandin E2 (PGE2) and corticosterone [5]. In A549
cells both quinidine (Fig. 4, panel A), inhibitor of OCT1 [10], and PGE2
(panel B), which preferentially inhibits OCT2 [5], were completely inef-
fective. On the contrary, the addition of corticosterone (panel C), which
can inhibit all OCTs, but has amuchhigher afﬁnity for OCT3 [5], was able
to signiﬁcantly reduce the uptake of 5 μM MPP+ in a concentration-
dependent manner (I0.5 = 1.29 μM; maximal inhibition N 90%). From
these data, the calculated Ki was 1.17 μM, a value very close to IC50 of
corticosterone for OCT3 [5]. Overall these results point to OCT3 as the
main transporter for MPP+ in A549 cells, excluding the contribution
of OCT1 and OCT2.
In NCl-H441 cells all the inhibitorswere ineffective at the concentra-
tions employed for A549 (data not shown). Hence, the inhibition analy-
sis has been performed at a higher concentration ofMPP+(50 μM)withysis. After normalization to RPL-15, the expression of SLC22A1/OCT1, and SLC22A3/OCT3 in
NA obtained from human kidney was employed as positive control and set =1. Data are
Fig. 11. SLC22A3/OCT3 silencing in A549 cells. A549 cells were transfectedwith scrambled
or SLC22A3/OCT3 siRNA for 96 h, as described in Material and methods. Panel A. The ex-
pression of SLC22A3/OCT3 mRNA was assessed by qRT-PCR and shown relatively to that
of untransfected cells (none=1). Data aremeans± S.E. of three separate determinations,
each performed in duplicate. **p b 0.01 vs untransfected cells (none). Panel B. The uptake
of [3H]MPP+ (5 μM; 2 μCi/ml; 5 min) was measured in cells untransfected (none) or
transfected with scrambled or SLC22A3/OCT3 siRNA. Data are means ± S.E. of three inde-
pendent experiments, each performed in quadruplicate. ***p b 0.01 vs scrambled siRNA.
Panel C. Transfected cells were incubated for 5 min in the transport buffer containing
[3H]MPP+ (5 μM; 2 μCi/ml) with the indicated concentrations of corticosterone. Each
point represents the mean ± S.D. of four independent determinations. Data were ﬁtted
by Eq. (3) (see section Material and methods). The experiment has been repeated twice
with comparable results.
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in Fig. 5, demonstrate that only quinidine modestly although signiﬁ-
cantly inhibited MPP+ uptake, with a maximal inhibition of about
30%. This ﬁnding points to OCT1 as the main transporter active in NCl-
H441 cells.
Due to the operation of different transport components in Calu-3
cells, the inhibition analysis in these cells had to be performed at differ-
ent concentrations of substrate, so as to properly identify the high and
low afﬁnity components. To choose the proper experimental conditions,
the relative contribution of the high and low afﬁnity components to
total MPP+ uptake has been calculated at different concentrations of
substrate, taking advantage of the proper kinetic parameters reported
in Table 1. As shown in Fig. 6 the contribution of the high afﬁnity trans-
porter was prevalent at low concentrations of substrate (up to 10 μM),
while the low afﬁnity activity accounted for more than 60% at
MPP+ N 100 μM. The effect of OCT inhibitors in Calu-3 has been hence
assessed at both 5 and 100 μM MPP+ (Fig. 7). At 5 μM MPP+ (left
panel), both corticosterone and quinidine inhibited the uptake, al-
though to a different extent (maximal inhibition of about 80% for corti-
costerone and 50% for quinidine). I0.5 values were in the order of
micromolar (1.038 and 3.98 μM for corticosterone and quinidine, re-
spectively). At 100 μMMPP+ (right panel), a concentration of substrate
that better highlights the low afﬁnity transport component, the percent
of maximal inhibition obtained by quinidine increased, while that of
corticosterone concomitantly decreased. PGE2 was always ineffective.
The results obtained from the inhibition analysis suggest that both
OCT1 and OCT3 are active in Calu-3 cells. In order to exclude the in-
volvement of other transporters such as OCTN1/2 and MATE1, the up-
take of MPP+ was measured (Fig. 8) at both low (5 μM, panels A and
B) and high (100 μM, panels C and D) concentrations of substrate,
both in the presence and in the absence of sodium, employing transport
buffer solutions at different pH (6.4, 7.4 and 8.4). Data obtained show
that MPP+ uptake was pH-independent and sodium-independent at
any value of pH, both at low and high substrate concentrations, thus ex-
cluding the contribution of MATE1, which is pH-dependent [24]. More-
over, carnitine and ergothioneine, the substrates of OCTN2 and OCTN1,
respectively [25,26], did not inhibit MPP+ uptake (panels B and D). We
thus conclude that in Calu-3 cells OCT3 represents the high afﬁnity
transporter for MPP+ while OCT1 accounts for the low afﬁnity
component.
The inhibition analysis on MPP+ transport has been, in addition,
performed in polarized Calu-3 cells maintained under air–liquid inter-
face grown conditions (Calu-3 ALI). The results, presented in Fig. 9,
demonstrate that at 5 μM MPP+ only corticosterone signiﬁcantly
inhibited the uptake at both basolateral and apical sides, while quini-
dine and PGE2 were ineffective (panels A and B). At 100 μM also quini-
dine, in addition to corticosterone, signiﬁcantly inhibited MPP+ uptake
at the apical side, while at the basolateral side only the inhibition by cor-
ticosteronewas signiﬁcant. In this latter condition PGE2was completely
ineffective and quinidine caused a slight, not signiﬁcant, inhibition
(panels C and D). These results suggest that OCT3 is functional at both
the basolateral and apical membranes in polarized Calu-3 cells, while
a signiﬁcant OCT1 activity is observed only at the apical side.
3.4. Expression of OCTs and MPP+ transport in silenced cells
Fig. 10 shows the expression of OCTs mRNA in A549, NCl-H441 and
Calu-3 cells. The level of OCT1was highest in Calu-3, with NCl-H441 fol-
lowing, and only barely detectable in A549. The expression of OCT2was
undetectable in all cell models while OCT3 was clearly evident in both
A549 and Calu-3 cells but not in NCl-H441.
In light of these results, we next employed short interfering RNA
(siRNA) to deﬁne the operation of OCT1 and OCT3 in A549 and Calu-3
cells. In A549 (Fig. 11), a signiﬁcant, although incomplete, silencing of
SLC22A3/OCT3 (about 40% comparedwith cells transfectedwith scram-
bled siRNA) was obtained after 96 h of incubation (panel A). Theobserved changes of gene expressionwere associatedwith amarked re-
duction of transport activity (N60%, panel B) in SLC22A3/OCT3 siRNA
transfected cells. In this latter condition, the corticosterone-inhibitable
fraction appeared much smaller compared to that observed in cells
transfected with scrambled siRNA (panel C). The silencing of SLC22A1/
OCT1 in this cell model was completely ineffective (result not shown).
These results, besides conﬁrming the prevalent operation of OCT3 in
A549 cells, also validate the efﬁcacy of corticosterone as OCT3 inhibitor.
Fig. 12 shows the effect of SLC22A1/OCT1 and SLC22A3/OCT3 silencing
on MPP+ transport activity in Calu-3 cells. As expected, OCT1 and
OCT3 siRNA were speciﬁcally effective in reducing the expression of
SLC22A1 (panel A) and SLC22A3 (panel B), respectively. The reduction
was about 50% for both genes. The consequence of gene silencing on
Fig. 12. SLC22A1/OCT1 and SLC22A3/OCT3 silencing in Calu-3 cells. Calu-3 cells were transfectedwith scrambled, SLC22A1/OCT1 or SLC22A3/OCT3 siRNA for 96 h, as described inMaterial
andmethods. Panels A and B. Relative expression of SLC22A1/OCT1 and SLC22A3/OCT3mRNA assessed by qRT-PCR and shown relatively to that of scrambled transfected cells (=1). Data
are means ± S.E. of three separate determinations, each performed in duplicate. **p b 0.01 vs scrambled transfected cells. Panels B and C. The uptake of [3H]MPP+ at 5 μM (panel C) or
100 μM (panel D) was measured. Data are means ± S.E. of two independent experiments, each performed in quadruplicate. *p b 0.05 vs scrambled siRNA.
1570 F. Ingoglia et al. / Biochimica et Biophysica Acta 1848 (2015) 1563–1572MPP+ transport was then evaluated by measuring substrate uptake at
5 μM(panel C) and 100 μM(panel D)MPP+. At 5 μM, only OCT3 silenc-
ing caused a signiﬁcant reduction ofMPP+ transportwhile OCT1 silenc-
ingwas ineffective. At 100 μMMPP+bothOCT1 andOCT3 siRNA caused
a modest (about 30%) although signiﬁcant inhibition of the transport.
These results conﬁrm the contribution of both OCT1 and OCT3 to
MPP+ transport in Calu-3 cells.
3.5. Characterization of MPP+ transport in bronchial BEAS-2B epithelial
cells
The characterization of MPP+ transport has been performed also in
a model of immortalized epithelial cells derived from normal lung
(BEAS-2B). Panel A of Fig. 13 shows that also in these cells MPP+ trans-
port is saturable and almost linear for 60 min. Kinetic analysis per-
formed both in the absence and in the presence of extracellular
sodium revealed the presence of at least two saturable transport com-
ponents, one displaying a very high-afﬁnity for the substrate
(Km ≤ 1 μM) and the other with a lower afﬁnity (Km of ~0.1 mM).
Both components are endowed with fairly low values of Vmax (0.0025
and 0.045 nmol/mg of protein/min, respectively). The inhibition analy-
sis has been, hence, performed at two different concentration of MPP+,
so as to properly identify these components. Both at 1 μM (panel C) and
50 μM (panel D) MPP+ corticosterone and quinidine signiﬁcantly
inhibited MPP+ transport, with a higher effect of corticosterone at the
lowest concentration and a predominant effect of quinidine at 50 μM
MPP+. PGE2 was ineffective. These results point to OCT3 and OCT1 as
transporters for MPP+ in BEAS-2B cells.
4. Discussion
The aim of the present study was to deﬁne the functional activity
and the expression of organic cation transporters (OCTs) in in vitro pul-
monary cell models, that could ultimately be employed for studies
concerning drug transportation in the lung. In this context, clear-cut
differences have been highlighted at functional level among theconsidered human airway epithelial cell models. In particular, A549
cells appear the ones displaying the more sustained uptake of MPP+,
which is mediated by a single high-afﬁnity transporter, as indicated by
the results of the kinetic analysis (see Fig. 3). The inhibition analysis of
MPP+ uptake reveals the efﬁcacy of the sole corticosterone, with a Ki
value consistent with the afﬁnity of corticosterone for OCT3 [5]. More-
over the use of speciﬁc siRNA targeting SLC22A3/OCT3 conﬁrms that
this is the transporter functionally operative in MPP+ uptake in A549
cells. In support of functional data, mRNA expression shows that only
OCT3 is clearly expressed in these cells. Our results are in line with pre-
vious ﬁndings by other groups [27,28], while different conclusions have
been reached by Salomon et al.when addressing OCT transport activity
employing theﬂuorescent organic cation 4-(4-(dimethylamino)styryl)-
N-methylpyridinium iodide (Asp+) as substrate [16]. The authors stat-
ed, indeed, that Asp+uptakewashigher inA549 than in other cell types
(Calu-3, 16HBE14o- and Caco-2 cells), a result in agreement with our
data with MPP+; however, their kinetic analysis indicated the involve-
ment of two different transport components, and both OCT2 and, prob-
ably, OCT3 were found active in these cells. We can presume that these
discrepancies are likely due to a different speciﬁcity ofMPP+andAsp+
towards OCTs, since the ﬁrst is a speciﬁc substrate of OCTs, while differ-
ent transporters, such as OCTN, may be involved in Asp+ uptake, as
demonstrated by the same authors [16].
Data obtained in Calu-3 cells point, instead, to the involvement of
more than one transporter in MPP+ uptake. Kinetic analysis indicates
the contribution of two saturable components to total uptake, with a
high (Km b 20 μM) and a low (Km N 0.6 mM) afﬁnity for the substrate.
The elaboration of the kinetic parameters allowedus to estimate the rel-
ative contribution of the two transport components at any concentra-
tion of substrate (see Fig. 6), that in turn enabled the selection of the
optimal discriminating conditions for the inhibition analysis: at low
concentrations of MPP+, the contribution of the high afﬁnity compo-
nent appears largely predominant, and the inhibition by corticosterone
identiﬁes OCT3 as the high afﬁnity transporter (see Fig. 7, left). Con-
versely, when MPP+ transport is measured at higher concentration
(100 μM), where the low afﬁnity component becomes predominant,
Fig. 13. Characterization of MPP+ uptake in BEAS-2B cells. Panel A. BEAS-2B cells were incubated for the indicated times in the transport buffer (see Material and methods) containing
[3H]MPP+ (10 μM; 2 μCi/ml) (open symbols). Non-speciﬁc binding of the substrate was estimated by measuring [3H]MPP+ uptake in the presence of an excess of unlabelled substrate
(2mM, ﬁlled symbols). Each point represents themean± S.D. of four independent determinations. Panel B. Cells were incubated in the presence of the indicated concentrations (from 0.8
to 1850 μM) of [3H]MPP+ (2 μCi/ml) for 15min in the absence (open symbols) or in the presence (ﬁlled symbols) of Na+. Nonlinear ﬁtting of the data was performed employing Eq. (2)
(see Material and methods). Insert shows the Eadie–Hofstee transformations of the saturable uptake (obtained after subtraction of the diffusive component estimated by the nonlinear
ﬁtting). Curves represent the nonlinear ﬁtting of the data. Straight lines are drawn employing the values of the kinetic parameters given by nonlinear regression. Points are mean ±
S.D. of three independent determinations. The experiment has been repeated twice with comparable results. Panels C and D. Cells were incubated for 15min in the transport buffer con-
taining1 μM(panel C) or 50 μM(panel D) [3H]MPP+(2 μCi/ml) in thepresenceof the indicated concentrations of the inhibitors. Eachpoint represents themean±S.D. of four independent
determinations. The experiment has been repeated three times with comparable results.
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ity transporter (see Fig. 7, right). The use of speciﬁc siRNA conﬁrmed
these ﬁndings (see Fig. 12). mRNA expression (see Fig. 10) excludes
the presence of OCT2 in these cells, in line with previous observations
by other groups [16,29,30]. Moreover, the pH-independency and the
lack of inhibition of carnitine and ergothioneine on MPP+ transport,
allow excluding the contribution of MATE1 and OCTNs to the transport
of MPP+ in this cell model. We conclude that OCT1 and OCT3 are the
ones functionally active in Calu-3, both when unpolarized (i.e. grown
onplasticware) andpolarized (i.e. grownunder air–liquid interface con-
dition, ALI). As far as this latter condition is concerned, we next ad-
dressed the cellular localization of the transporters, basolateral rather
than apical, an issue, thus far, only roughly deﬁned. To this concern, per-
meation approaches performedbyMukherjee et al., by employing Asp+
as substrate, suggested the presence of an OCT activity only at the apical
side of Calu-3 cells; since the dye was not signiﬁcantly transported
across themonolayers from the apical into the basolateral compartment
of the transwell chambers, they excluded OCT activity at the basolateral
side of the cells [30]. Conversely, a similar study by MacDonald et al.
showed that Asp+ is not only actively taken up at both sides of the
cells, but it is also transported across the monolayer with a ﬂux from
apical versus basolateral signiﬁcantly higher than the opposite [29].Accordingly, our results in Calu-3 ALI indicate a bi-directional transfer
of MPP+ into the opposite compartment, which is mediated by both
OCT1 and OCT3 at the apical and by OCT3 at the basolateral side of the
monolayer.
As far as NCl-H441 cells are concerned, results obtained appear pecu-
liar, since only OCT1 is expressed and a very modest saturable uptake of
MPP+ is measurable. Accordingly, results of the kinetic analysis clearly
indicate that MPP+ uptake is mediated by a single saturable component
endowed with a relatively high afﬁnity (Km = 180 μM) and a very low
value of Vmax (about ten times lower than that measured in A549 cells).
The transport activity could be, hence, ascribed to a non-saturable, rather
than to an active component; however, themodest, but signiﬁcant, inhib-
itory effect of quinidine and the lack of inhibition by corticosterone and
PGE2 conﬁrm that OCT1 is responsible of MPP+ uptake in NCl-H441
cells. Recently, Salomon et al. reported a Km in the similar order of magni-
tude (881.2 ± 195.3 μM) and a Vmax much higher than our (2.07 ±
0.26 nmol/min/mg protein) for Asp+ uptake [20]. Whether these differ-
ences could be explained by the involvement of other transporters or by a
different speciﬁcity of the two substrates employed remains to be
established. Finally,we present here for theﬁrst time, a functional charac-
terization ofMPP+ transport in amodel of immortalized human bronchi-
al epithelial cells (BEAS-2B), a line of cells obtained from normal lung.
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comparable to that of NCl-H441. On the other hand, kinetic and inhibition
analyses showa pattern of transport similar to that of Calu-3 cells. Further
studies are necessary to ascertainwhether differences amongOCT activity
in adenocarcinoma derived cell lines and normal cells actually exist and
can be ascribed to the malignant phenotype.
5. Conclusions
Overall, these results are of particular relevance for the deﬁnition of
the operative features of OCT transporters in organotypic in vitromodels
of human respiratory epithelium. Clear cut differences have been de-
tected among the considered airway epithelial cells as far as OCT ex-
pression and activity are concerned. In particular A549 and NCl-H441
cells appear suitable models for the study of drug interaction with the
sole OCT3 or OCT1, respectively. Conversely, the simultaneous contribu-
tion of OCT1 andOCT3 to cationic drug transport is appreciable in Calu-3
and BEAS-2B cells. All the cell models employed are unusable for studies
of drug interaction with OCT2, due to its lack of expression. These ﬁnd-
ings could, thus, help to identify the proper in vitromodel for researches
of drug absorption and disposition.
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